tailieunhanh - Báo cáo y học: " Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis"

Tham khảo luận văn - đề án 'báo cáo y học: " vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (als), with a potential role in disease pathogenesis"', luận văn - báo cáo phục vụ nhu cầu học tập, nghiên cứu và làm việc hiệu quả | Int. J. Med. Sci. 2008 5 92 International Journal of Medical Sciences ISSN 1449-1907 2008 5 2 92-99 Ivyspring International Publisher. All rights reserved Research Paper Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis ALS with a potential role in disease pathogenesis Zhong Zhao1 2 Dale J. Lange1 3 Lap Ho1 2 Sara Bonini1 2 Belinda Shao1 2 Stephen R. Salton4 5 Sunil Thomas1 2 and Giulio Maria Pasinetti1 2 4 5 1. James J. Peters Veterans Affairs Medical Center Bronx NY 10468 2. Departments of Psychiatry Mount Sinai School of Medicine New York NY-10029 3. Departments of Neurology Mount Sinai School of Medicine New York NY-10029 4. Departments of Neuroscience Mount Sinai School of Medicine New York NY-10029 5. Departments of Geriatrics Mount Sinai School of Medicine New York NY-10029 Correspondence to Dr. Giulio Maria Pasinetti Mount Sinai School of Medicine Department of Psychiatry One Gustave L. Levy Place Box 1668 New York NY-10029. Email Received Accepted Published Amyotrophic lateral sclerosis ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Previous proteomic evidence revealed that the content of certain peptide fragments including Vgf-derived peptide aa 398-411 V gf398-411 of the precursor Vgf protein in the cerebral spinal fluid CSF correctly identified patients with ALS from normal and disease controls. Using quantitative ELISA immunoassay we found that the CSF levels of Vgf decreases with muscle weakness in patients with ALS. In SOD1 G93A transgenic mice loss of full-length Vgf content in CSF serum and in SMI-32 immunopositive spinal cord motor neurons is noted in asymptomatic animals approximately 75 days old and continues to show a progressive decline as animals weaken. In vitro studies show that viral-mediated exogenous Vgf expression in primary mixed spinal cord neuron cultures .